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Abstract 
Background: Previous genome-wide association studies have evaluated the impact of common genetic vari-
ants and identified several non-HLA risk loci associated with autoimmune liver diseases. More recent genome-wide 
association studies and replication analyses reported an association between variants of the CARD10 polymorphism 
rs6000782 and risk of type 1 autoimmune hepatitis (AIH). In this case–control study, we genotyped 326 Japanese AIH 
patients and 214 control subjects.
Results: Genomic DNA from 540 individuals of Japanese origin, including 326 patients with type-1 AIH and 214 
healthy controls, was analyzed for two single nucleotide polymorphisms (SNPs) in the CARD10 gene. We selected 
CARD10 rs6000782 SNPs and genotyped these using PCR–RFLP method and direct sequencing. The Chi square test 
revealed that the rs6000782 variant alle (c) was not associated with the susceptibility for AIH in a Japanese population 
[p = 0.376, odds ratio (OR) 1.271, 95 % confidence interval (CI) 0.747–2.161] in an allele model. Our data also showed 
that CARD10 rs6000782 variants were not associated with AIH or with the clinical parameters of AIH.
Conclusions: In this study we examined an association between rs6000782 SNPs in the CARD10 gene and type-1 
AIH. Results showed no significant association of rs62000782 with type-1 AIH in a Japanese population. This study 
demonstrated no association between CARD10 rs6000782 variants and AIH in a Japanese population.
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Background
Autoimmune hepatitis (AIH) is characterized by the 
presence of serum antibodies, both anti-nuclear (ANA) 
and anti-smooth muscle antibodies (ASMA), as well as 
elevated immunoglobulin G levels, and interface hepati-
tis [1]. The genetic factors underlying the occurrence of 
AIH are unknown, with the exception of certain human 
leukocyte antigen (HLA) alleles [2]. de Boer et al. previ-
ously conducted a genome-wide association study that 
identified the most prominent association with AIH at 
rs2187668, which maps to the intronic region of HLA-
DQA1 [3]. They also showed that AIH was associated 
with variants of genes encoding Scr homology 2 adaptor 
protein 3 (SH2B3; rs3184504) and caspase recruitment 
domain-containing protein 10 (CARD10; rs6000782) [3]. 
In view of the importance of understanding the contri-
bution of genetics to AIH, we carried out a case–con-
trol study to investigate the association between variants 
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Consecutive type 1 AIH patients (n  =  326) diagnosed 
according to the international diagnostic criteria for AIH 
[4] from the register of the Japanese National Hospital 
Organization (NHO) Liver Network Registry beginning 
in 2009 were enrolled in the present study as a multi-
center cohort population [5]. Patients exhibiting primary 
biliary cirrhosis were excluded from the analysis. As 
controls, 214 healthy Japanese subjects (74 men and 140 
women, with a mean age of 47.5 ±  10.8  years) with no 
history of liver disease were also enrolled. All patients did 
not have any other types of liver diseases such as chronic 
hepatitis C, alcoholic liver diseases, autoimmune liver 
diseases, or metabolic liver diseases. This study was con-
ducted by adhering to the STOROBE statement (case–
control studies). The study protocol was approved by the 
Ethics Committees of National Nagasaki Medical Center, 
and written informed consent was obtained from each 
individual.
DNA extraction and genotyping
Blood samples were taken from all study participants, and 
genomic DNA was isolated from peripheral blood leuko-
cytes using a DNA blood mini kit from Qiagen (Hilden, 
Germany) according to the manufacturer’s guidelines. 
CARD10 rs6000782 genotypes were determined by the 
polymerase chain reaction–restriction fragment length 
polymorphism (PCR–RFLP) method. For the sequence 
(Fig.  1a), PCR products were treated with ExoSAP-IT 
(Affymetrix, Inc., Santa Clara, CA), and then sequenced 
using a BigDye Terminator v1.1 Cycle Sequencing Kit 
(Life Technologies, Tokyo, Japan). Sequences were ana-
lyzed using an Applied Biosystems 3130xl Genetic Ana-
lyzer (Life Technologies). Restriction fragment length 
polymorphism analysis was performed after the iden-
tification of single nucleotide polymorphism-specific 
restriction sites by NCBI Entrez SNP (http://www.ncbi.
nlm.nih.gov/snp) and Takara Cut-Site Navigator (http://
www.takara-bio.co.jp/enzyme). PCR restriction frag-
ment length polymorphism genotyping to detect the 
37928186A  >  C base pair change was performed using 
the following cycling profile: 95 °C for 5 min, followed by 
35 cycles at 95 °C for 1 min, 56 °C for 1 min, and 72 °C for 
1 min. The 365-base pair product was digested with XspI 
at 37 °C for 6 h and analyzed by 4 % NuSieve 3:1 agarose 
gel electrophoresis (Fig. 1b).
Statistical analyses
Results are expressed as mean ± SD. The statistical sig-
nificance of differences between groups was calculated by 
either the Chi square test or Fisher’s exact test for cate-
gorical data and Mann–Whitney’s U test for quantitative 
data. Multivariate logistic regression analysis was per-
formed with SPSS v.18 for windows (SPSS Statistics, Illi-
nois). Deviation from Hardy–Weinberg equilibrium was 
assessed using the SNPAlyze software ver. 7.0 (Dynacom, 
Fig. 1 Genotyping of CARD10 rs6000782. a CARD10 rs6000782 is positioned 12,643 base pairs downstream in the 22q13.1 region. For sequencing 
primers, forward primer 5′-TTGAGACGGGGTCTCGCT-3′ and reverse primer 5′-GCCAAACCCGAGGTAATCTA-3′. b The SNP CARD10 rs6000782 A/C 
were genotyped from a PCR fragment with an average size of 365 bp. The dimorphism rs6000782 A/C was typed by RFLP method, the amplified 
PCR product was digested with XspI restriction enzyme, resulting in 321 and 24 and 20 bp fragments for allele C and an intact fragment of 345 and 
20 bp for allele A. The small fragments (<50 bp) are not visible on the gel
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Yokohama, Japan). A p value of  <0.05 was considered 
significant.
Results
Demographic data of patients with AIH
Table  1 presents the demographic data of the subjected 
AIH patients. Among the enrolled type-1 AIH patients, 
288 (88.6  %) were positive for ANA (>1:40) and 121 
(38.2 %) for ASMA (>1:40). Among 326 eligible patients, 
35 (10.7  %) had liver cirrhosis at the time of diagnosis, 
and among the remaining 291 patients without liver cir-
rhosis, 16 developed liver cirrhosis during the follow-up.
Association of CARD10 polymorphisms with type‑1 AIH
Genotype distributions were in Hardy–Weinberg equi-
librium in cases and controls (Table  2). Genotype fre-
quencies and distributions, as well as odds ratios (ORs) 
and 95  % confidence intervals (CIs) for the association 
with AIH are shown in Table  3. The rs6000782 C allele 
was shown not to be associated with an increased risk for 
AIH (OR 1.271; 95 % CI 0.747–2.161; p = 0.376).
We also performed a detailed genotype–phenotype 
analysis using the clinical data. A detailed genotype–phe-
notype analysis using the clinical data revealed no signifi-
cant association between rs6000782 and clinical findings 
of AIH patients (Table 4).
Discussion
AIH is characterized by an imbalanced regulation of the 
immune system in which innate and adaptive immune 
responses to hepatocyte antigens are important [6]. 
Genetic variation in the immune mechanisms that estab-
lish and maintain self-tolerance is likely to play a role in 
the development of AIH [7]. The susceptibility genes of 
AIH act alone or with environmental factors whose iden-
tity is mostly unknown [8]. The strongest association is 
with genes located within the HLA region, particular-
ity those encoding the HLA-DRB1 alleles [2]. Up until 
now, evaluation of the non-HLA genetics of AIH has 
focused on small scale (usually non-replicated) candidate 
gene studies [9]. Genome-wide screening is a promising 
approach for the identification of the genetic determi-
nants of complex diseases [8]. Large case–control stud-
ies with genome-wide surveys of genetic risk have been 
demonstrated for primary biliary cirrhosis (PBC) [10, 11]. 
AIH was subjected to the a similar genome-wide survey. 
Table 1 Baseline characteristics of 326 Japanese AIH type 
1 patients
AST aspartate aminotransferase, ALT alanine aminotransferase, ALP alkaline 
phosphate, IgG immunoglobulin G, ANA anti-nuclear antibody, ASMA 
anti-smooth muscle antibody, IQR interquartile range, IAIHG International 
Autoimmune Hepatitis Group
Characteristics N = 326 (%)
Female, n/total (%) 289/326 (88.7)
Age, years, mean ± SD 59.5 ± 13.3
Biochemistry
 AST, IU/L, median (IQR) 255.0 (92.5–723.0)
 ALT, IU/L, median (IQR) 297.0 (104.5–818.0)
 ALP, IU/L, median (IQR) 432.0 (316.5–584.0)
 Total Bilirubin, mg/dl, median (IQR) 1.3 (0.8–4.6)
 Albumin, g/dl, median (IQR) 3.9 (3.5–4.2)
 IgG, mg/dl, median (IQR) 2239.0 (1809.5–2390.0)
 Platelets, 104/μl, median (IQR) 18.5 (13.9–23.0)
Serology
 ANA ≧ 1:40, n/total (%) 288/325 (88.6)
 ASMA ≧ 1:40, n/total (%) 121/317 (38.2)
Histology
 Cirrhosis, n/total (%) 51/326 (15.6)
IAIHG criteria
 Score, median (IQR) 16 (14–18)
 Probable AIH, n/total (%) 126/309 (40.8)
 Definite AIH, n/total (%) 183/309 (59.2)
Table 2 Frequencies of CARD10 rs6000782 genotypes
a Expected genotype frequencies based on observed allele frequencies and assuming Hardy–Weinberg equilibrium
b p values were calculated using the Chi square test for Hardy–Weinberg equilibrium at individual loci




 n = 326 rs6000782 A/A 284 (87.1) 285.3 χ2 = 1.746
A/C 42 (12.9) 39.3 p = 0.523
C/C 0 1.4
Healthy control
 n = 214 rs6000782 A/A 193 (90.2) 192.5 χ2 = 0.280
A/C 20 (9.3) 20.9 p = 1.000
C/C 1 (0.5) 0.6
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The first application for type 1 AIH by de Boer et al. in 
AIH patients identified three genes exhibiting significant 
association in 649 patients and 13,436 healthy controls in 
Dutch and German populations. The main finding of this 
study was the strength of the AIH association with HLA, 
although it also identified associations with the SH2B3 
rs3184504 *A allele and CARD10 rs6000782 *C allele.
The present study found no association of CARD10 
rs6000782 variants with type 1 AIH in a Japanese popu-
lation. The major strength of this study is the finding 
that the association discovers by deBoer in a Caucasian 
Northern European Dutch and German population is 
not generalizable to the East Asian Japanese population. 
While this contrasts with the finding of de Boer et al. in 
a Caucasian population, it is in agreement with the docu-
mented lack of association between CARD10 variants 
and AIH in populations of diverse racial backgrounds. 
Gene–gene interactions or epistasis have been pro-
posed to occur between genes that cluster within specific 
immune pathways, thus enhancing their effect on disease 
susceptibility [12]. These have been reported in autoim-
mune diseases, including a possible interaction between 
HLA and non-HLA genes [13]. This suggests that further 
gene–gene interaction studies will be necessary to deter-
mine the associations of different susceptibility loci in 
AIH.
The main finding of the study by de Bore et  al. [3] 
remains the relative strength of the HLA associa-
tions. The associations of AIH with variants of SH2B3 
rs3184504 (p  =  7.7  ×  10−8) and CARD10 rs6000782 
(p = 3.0 × 10−6) did not reach the accepted level of sig-
nificance required to declare genome-wide significance 
(p < 5 × 10−8). However, the prior association of SH2B3 
variants with autoimmune diseases suggests that this 
association is likely to be confirmed with larger cohorts. 
We did not analyze the association of SH2B3 rs3184504 
and AIH in our current study because it is almost mono-
morphic in a Japanese population (http://www.ncbi.nlm.
nih.gov/projects/SNP/snp_ref.cgi?rs=3184504). How-
ever, such validation is necessary because attempts to 
Table 3 CARD10 rs6000782 polymorphism in  patients 
with type 1 AIH and healthy controls
OR odds ratio, CI confidence interval
a Genotype frequencies were determined by χ2 test using 2 × 3 contingency 
tables between patients with AIH and healthy controls. Allele frequencies were 











 A/A 193 (90.2) 284 (87.1)
 A/C 20 (9.3) 42 (12.9)




 A 406 (94.9) 610 (93.6) 1
 C 22 (5.1) 42 (6.4) 1.271 (0.747–
2.161)
Table 4 Comparison of demographics between AIH patients with or without rs6000782 C allele
AST aspartate aminotransferase, ALT alanine aminotransferase, ALP alkaline phosphate, IgG immunoglobulin G, ANA anti-nuclear antibody, ASMA anti-smooth muscle 
antibody, IQR interquartile range
rs6000782 C allele (+) rs6000782 C allele (−) p
n = 42 n = 284
Female, n (%) 38 (90.5) 251 (88.4) 0.465
Age, years, mean ± SD 59.6 ± 13.9 59.5 ± 13.3 0.786
Biochemistry
 AST, IU/L [median (IQR)] 189.0 (85.5–835.0) 264.0 (94.0–707.5) 0.620
 ALT, IU/L [median (IQR)] 258.5 (93.0–906.0) 305.0 (104.5–813.0) 0.926
 ALP, IU/L [median (IQR)] 402.5 (261.0–566.0) 437.0 (323.5–586.5) 0.242
 Total bilirubin, mg/dl [median (IQR)] 1.9 (0.8–4.6) 1.2 (0.8–4.6) 0.680
 Albumin, g/dl [median (IQR)] 3.9 (3.4–4.2) 3.9 (3.5–4.2) 0.844
 IgG, mg/dl [median (IQR)] 2078.0 (1695.0–2691.5) 2250.0 (1835.5–2945.0) 0.199
 Platelets, 104/μl [median (IQR)] 19.6 (15.1–22.4) 18.4 (13.9–23.1) 0.712
Serology
 ANA ≧ 1:40, n (%) 36 (85.7) 252 (89.0) 0.339
 ASMA ≧ 1:40, n (%) 13 (31.0) 108 (39.3) 0.301
Histology
 Cirrhosis, n (%) 8 (19.0) 43 (15.1) 0.515
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generalize genetic associations across ethnicities have 
had mixed results. For CARD10 rs6000782, more vali-
dation studies are warranted. Our study only enrolled 
patients with a definite diagnosis of AIH, in order to pre-
vent any potential case ascertainment bias. This approach 
limited the sample size and therefore introduced the 
limitation of reduced statistical power, which might have 
prevented us from identifying potential associations 
between CARD10 rs6000782 and AIH.
Conclusions
Our findings showed that CARD10 rs6000782 is not 
likely to be associated with type 1 AIH, at least in a Japa-
nese population. However, because allele frequency dis-
tributions differ according to ethnicity, replication in 
other populations and functional studies should be ini-
tiated in order to clarify the contribution of this genetic 
background in the development of AIH . Genetic varia-
tions associated with AIH susceptibility remain for fur-
ther investigation.
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